Seeking Alpha

Piper Jaffray weighs in on Sarepta's (SRPT +5.3%) earlier data update on its Phase IIb study of...

Piper Jaffray weighs in on Sarepta's (SRPT +5.3%) earlier data update on its Phase IIb study of on eteplirsen saying its very encouraged as there are no treatment options for DMD. The primary near-term value driver in the stock is SRPT's decision to file for accelerated approval later this month. Piper projects a 50/50 chance it will be able to file on existing data.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs